{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034876","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.114405+00:00","generated_at":"2026-05-15T08:48:54.061713+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine","bullets":["Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.","Completed enrollment in Phase 2 START trial in early Alzheimer's; topline results expected in 2027.","FDA Division of Psychiatry meeting anticipated by mid-2026 to discuss registrational plan for zervimesine in DLB psychosis.","Launched expanded access program for DLB patients following a philanthropic donation.","Appointed Dr. David Weinstein as VP of clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034876","json":"https://secwatch.observer/filing/0001104659-26-034876.json","markdown":"https://secwatch.observer/filing/0001104659-26-034876.md","text":"https://secwatch.observer/filing/0001104659-26-034876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/0001104659-26-034876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/tm269805d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T08:48:54.061713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ca2fdb90a1ddbef62096e524171af4e197f094b","claim":"COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.","evidence_excerpt":"$12.3 million for 2024. The change in general and administrative expenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5 million, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or $(0.86) per basic and diluted share for 2024. Conference","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/0001104659-26-034876-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$23.5 million, or $(0.32) per basic and diluted share"},{"label":"EPS","value":"$(0.32) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}